Government Tells High Court Not To Review Drug Trademark Dispute
WASHINGTON, D.C. — The federal government argues in a Jan. 24 opposition brief that the U.S. Supreme Court should not review a ruling that held Bayer Consumer Care AG (BCC) and...To view the full article, register now.
Already a subscriber? Click here to view full article